AN2 Therapeutics, Inc. (ANTX)
- Previous Close
2.2800 - Open
2.3000 - Bid 2.2900 x 100
- Ask 2.3600 x 100
- Day's Range
2.2000 - 2.3700 - 52 Week Range
2.2000 - 22.2200 - Volume
120,570 - Avg. Volume
475,763 - Market Cap (intraday)
69.067M - Beta (5Y Monthly) -0.24
- PE Ratio (TTM)
-- - EPS (TTM)
-2.7400 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
16.00
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, which is in a pivotal Phase 2/3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease. The company also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize, or otherwise exploit certain compounds and products, including epetraborole, for the treatment, diagnosis, or prevention of all human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize certain compounds and products, including epetraborole, in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
www.an2therapeutics.comRecent News: ANTX
Performance Overview: ANTX
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ANTX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ANTX
Valuation Measures
Market Cap
69.07M
Enterprise Value
-26.18M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.55
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
0.38
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-36.07%
Return on Equity (ttm)
-58.83%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-64.73M
Diluted EPS (ttm)
-2.7400
Balance Sheet and Cash Flow
Total Cash (mrq)
107.3M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-28.85M